IP Library Granted Patent US 12,229,834
Granted Patent B1
US 12,229,834 · App. 17/676,437 · Granted Feb 18, 2025

Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction

Inventors: Phillip Draa (Atlanta, GA); Jared Burdine (Dunwoody, GA); John Giglio (Brookhaven, GA)
Assignee: MCKESSON CORPORATION
G06Q40/08G06Q30/0283
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,229,834
App. No.
17/676,437
Granted
Feb 18, 2025
Kind
B1
Abstract

A method, apparatus and computer program product are provided for partitioning prescription transaction costs in an electronic prescription transaction by determining a credit amount to be applied to an adjudicated prescription claim. The credit amount may be applied based on a co-pay amount provided by an adjudication computer and/or historical data, and may be adjusted according to an alternative cost obtained from an alternative cost data source. The alternative cost may be a cost for which a government sponsored plan can obtain the prescription. The remaining patient pay amount may be transmitted to a pharmacy computer such that a patient can purchase the prescription for a discounted cost.

Claims (54)

1. An apparatus comprising at least one processor and at least one memory including computer program code, the at least one memory and the computer program code configured to, with the at least one processor, cause the apparatus to at least:

receive, at a service provider computer and from a pharmacy computer, an indication of a prescription transaction comprising a patient identifier identifying a patient and a prescription identifier identifying a drug; and

in real-time or near real-time relative to receiving the indication of the prescription transaction, and by the service provider computer:

access an alternative cost data source to determine an alternative cost of the drug available via an alternative system associated with a government-sponsored payer;

transmit a prescription claim associated with the prescription transaction to an adjudication computer identified from a plurality of adjudication computers based on insurance information provided in the prescription transaction;

receive an adjudicated prescription claim associated with the prescription transaction, the adjudicated prescription claim comprising a co-pay amount;

determine a preliminary remaining patient pay amount by applying a predefined target adherence rate to a price sensitivity model;

determine a preliminary credit amount as the co-pay amount minus the preliminary remaining patient pay amount determined by applying a predefined target adherence rate to the price sensitivity model;

determine that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system;

in response to determining that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system, adjust the preliminary credit amount by applying a predefined target adherence rate to the price sensitivity model, wherein the preliminary credit amount is adjusted to a credit amount that would result in a payer cost that is greater than or equal to the alternative cost;

determine a remaining patient pay amount by applying the credit amount to the preliminary credit amount determined based on at least the price sensitivity model;

in response to determining the remaining patient pay amount based at least on the price sensitivity model, reformat the adjudicated prescription claim to a format that includes the remaining patient pay amount and the credit amount, and that is readable by the pharmacy computer; and

cause transmission of the adjudicated prescription claim including the remaining patient pay amount and the credit amount to the pharmacy computer.

2. The apparatus of claim 1 , wherein the alternative cost of the drug is determined by accessing historical data.

3. The apparatus of claim 1 , wherein the preliminary credit amount is calculated in order to improve adherence rates.

4. The apparatus of claim 1 , wherein the alternative system is a government funded system.

5. The apparatus of claim 1 , wherein the at least one memory and the computer program code are further configured to, with the at least one processor, cause the apparatus to at least:

cause transmission of the credit amount to at least one of the pharmacy computer or a third party computer.

6. A method comprising:

receiving, at a service provider computer and from a pharmacy computer, an indication of a prescription transaction comprising a patient identifier identifying a patient and a prescription identifier identifying a drug; and

in real-time or near real-time relative to receiving the indication of the prescription transaction, and by the service provider computer:

accessing an alternative cost data source to determine an alternative cost of the drug available via an alternative system associated with a government-sponsored payer;

transmitting a prescription claim associated with the prescription transaction to an adjudication computer identified from a plurality of adjudication computers based on insurance information provided in the prescription transaction;

receiving an adjudicated prescription claim associated with the prescription transaction, the adjudicated prescription claim comprising a co-pay amount;

determining a preliminary remaining patient pay amount by applying a predefined target adherence rate to a price sensitivity model;

determining a preliminary credit amount as the co-pay amount minus the preliminary remaining patient pay amount determined by applying a predefined target adherence rate to the price sensitivity model;

determining that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system;

in response to determining that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system, adjusting the preliminary credit amount by applying a predefined target adherence rate to the price sensitivity model, wherein the preliminary credit amount is adjusted to a credit amount that would result in a payer cost that is greater than or equal to the alternative cost;

determining a remaining patient pay amount by applying the credit amount to the preliminary credit amount determined based on at least the price sensitivity model;

in response to determining the remaining patient pay amount based at least on the price sensitivity model, reformatting the adjudicated prescription claim to a format that includes the remaining patient pay amount and the credit amount, and that is readable by the pharmacy computer; and

causing transmission of the adjudicated prescription claim including the remaining patient pay amount and the credit amount to the pharmacy computer.

7. The method of claim 6 , wherein the alternative cost of the drug is determined by accessing historical data.

8. The method of claim 6 , wherein the preliminary credit amount is calculated in order to improve adherence rates.

9. The method of claim 6 , wherein the alternative system is a government funded system.

10. The method of claim 6 , further comprising:

causing transmission of the credit amount to at least one of the pharmacy computer or a third party computer.

11. A computer program product comprising at least one non-transitory computer-readable storage medium having computer-executable program code instructions stored therein, the computer-executable program code instructions comprising program code instructions to:

receive, by a service provider computer and from a pharmacy computer, an indication of a prescription transaction comprising a patient identifier identifying a patient and a prescription identifier identifying a drug; and

in real-time or near real-time relative to receiving the indication of the prescription transaction:

access an alternative cost data source to determine an alternative cost of the drug available via an alternative system associated with a government-sponsored payer;

transmit a prescription claim associated with the prescription transaction to an adjudication computer identified from a plurality of adjudication computers based on insurance information provided in the prescription transaction;

receive an adjudicated prescription claim associated with the prescription transaction, the adjudicated prescription claim comprising a co-pay amount;

determine a preliminary remaining patient pay amount by applying a predefined target adherence rate to a price sensitivity model;

determine a preliminary credit amount as the co-pay amount minus the preliminary remaining patient pay amount determined by applying a predefined target adherence rate to the price sensitivity model;

determine that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system;

in response to determining that the preliminary credit amount would result in a payer cost that is lower than the alternative cost of the drug available via the alternative system, adjust the preliminary credit amount by applying a predefined target adherence rate to the price sensitivity model, wherein the preliminary credit amount is adjusted to a credit amount that would result in a payer cost that is greater than or equal to the alternative cost;

determine a remaining patient pay amount by applying the credit amount to the preliminary credit amount determined based on at least the price sensitivity model;

in response to determining the remaining patient pay amount based at least on the price sensitivity model, reformat the adjudicated prescription claim to a format that includes the remaining patient pay amount and the credit amount, and that is readable by the pharmacy computer; and

cause transmission of the adjudicated prescription claim including the remaining patient pay amount and the credit amount to the pharmacy computer.

12. The computer program product of claim 11 , wherein the alternative cost of the drug is determined by accessing historical data.

13. The computer program product of claim 11 , wherein the preliminary credit amount is calculated in order to improve adherence rates.

14. The computer program product of claim 11 , wherein the alternative system is a government funded system.

15. The computer program product of claim 11 , wherein the computer-executable program code instructions further comprise program code instructions to:

cause transmission of the credit amount to at least one of the pharmacy computer or a third party computer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2022
From: DRAA, PHILLIP; BURDINE, JARED; GIGLIO, JOHN
To: MCKESSON CORPORATION
Reel/Frame 059057/0057 →
Continuity (1)
Continuation In Part 16792413 · Feb 17, 2020
References Cited (400)
US 5012035A · Sartori et al. · 1991 [cited by applicant]
US 5173851A · Off et al. · 1992 [cited by applicant]
US 5595342A · McNair et al. · 1997 [cited by applicant]
US 5628530A · Thornton · 1997 [cited by applicant]
US 5726092A · Mathews et al. · 1998 [cited by applicant]
US 5757898A · Nishikawa · 1998 [cited by applicant]
US 5769228A · Wroblewski · 1998 [cited by applicant]
US 6012035A · Freeman et al. · 2000 [cited by applicant]
US 6111218A · Akers et al. · 2000 [cited by applicant]
US 6463462B1 · Smith et al. · 2002 [cited by applicant]
US 6595342B1 · Maritzen et al. · 2003 [cited by applicant]
US 6726092B2 · Goldberg et al. · 2004 [cited by applicant]
US 6757898B1 · Ilsen et al. · 2004 [cited by applicant]
US 6769228B1 · Mahar · 2004 [cited by applicant]
US 7155397B2 · Alexander et al. · 2006 [cited by applicant]
US 7192741B2 · Otte et al. · 2007 [cited by applicant]
US 7337129B1 · Lowry et al. · 2008 [cited by applicant]
US 7346768B2 · DiRienzo · 2008 [cited by applicant]
US 7409632B1 · DiRienzo · 2008 [cited by applicant]
US 7426476B2 · Munoz et al. · 2008 [cited by applicant]
US 7734483B1 · Smith et al. · 2010 [cited by applicant]
US 7783383B2 · Eliuk et al. · 2010 [cited by applicant]
US 7840424B2 · Wiley et al. · 2010 [cited by applicant]
US 7856364B1 · Wiley et al. · 2010 [cited by applicant]
US 7912741B1 · Pinsonneault · 2011 [cited by applicant]
US 7921021B1 · Newman · 2011 [cited by applicant]
US 8036913B1 · Pinsonneault · 2011 [cited by examiner]
US 8036914B1 · Pinsonneault · 2011 [cited by applicant]
US 8036918B1 · Pinsonneault · 2011 [cited by applicant]
US 8050943B1 · Wiley et al. · 2011 [cited by applicant]
US 8060379B1 · Pinsonneault et al. · 2011 [cited by applicant]
US 8126743B1 · Wilk · 2012 [cited by applicant]
US 8326773B1 · Bellamy · 2012 [cited by applicant]
US 8412537B1 · Fenton et al. · 2013 [cited by applicant]
US 8442847B1 · Shrivastava · 2013 [cited by applicant]
US 8489415B1 · Ringold · 2013 [cited by applicant]
US 8521557B1 · Ringold et al. · 2013 [cited by applicant]
US 8560340B1 · Ringold · 2013 [cited by applicant]
US 8645162B2 · Boerger et al. · 2014 [cited by applicant]
US 8671018B2 · Thomas et al. · 2014 [cited by applicant]
US 8712797B1 · Bezdek et al. · 2014 [cited by applicant]
US 8738399B1 · Abou Nader et al. · 2014 [cited by applicant]
US 8786650B1 · Eller et al. · 2014 [cited by applicant]
US 8799018B1 · Rea et al. · 2014 [cited by applicant]
US 8984059B2 · Johnson · 2015 [cited by applicant]
US 9026507B2 · Shraim et al. · 2015 [cited by applicant]
US 9100793B2 · Johnson · 2015 [cited by applicant]
US 9171322B2 · Spievak et al. · 2015 [cited by applicant]
US 9356947B2 · Shraim et al. · 2016 [cited by applicant]
US 9760871B1 · Pourfallah et al. · 2017 [cited by applicant]
US 9786023B2 · Cohan et al. · 2017 [cited by applicant]
US 10109027B1 · Stack · 2018 [cited by applicant]
US 10157262B1 · Pinsonneault · 2018 [cited by applicant]
US 10331855B1 · Bratton · 2019 [cited by examiner]
US 10417380B1 · Kaye et al. · 2019 [cited by applicant]
US 10489552B2 · Pinsonneault · 2019 [cited by applicant]
US 10496793B1 · Lawrence et al. · 2019 [cited by applicant]
US 10565656B1 · Pinsonneault et al. · 2020 [cited by applicant]
US 10606984B1 · Kaye et al. · 2020 [cited by applicant]
US 10616146B1 · Hopkins et al. · 2020 [cited by applicant]
US 10628797B2 · Shraim et al. · 2020 [cited by applicant]
US 10642812B1 · Hopkins et al. · 2020 [cited by applicant]
US 10713694B1 · Harris · 2020 [cited by examiner]
US 10747848B2 · Guinan · 2020 [cited by applicant]
US 10778618B2 · Karnin et al. · 2020 [cited by applicant]
US 10862832B1 · Harris · 2020 [cited by applicant]
US 10924545B2 · Momchilov et al. · 2021 [cited by applicant]
US 10924585B1 · Harris et al. · 2021 [cited by applicant]
US 10929932B1 · Golden et al. · 2021 [cited by applicant]
US 10978198B1 · Pinsonneault · 2021 [cited by applicant]
US 10999224B1 · Frechen et al. · 2021 [cited by applicant]
US 11043293B1 · Salzbrenner · 2021 [cited by applicant]
US 11443835B1 · Gangaikondan-Iyer et al. · 2022 [cited by applicant]
US 11508471B1 · Anselmi et al. · 2022 [cited by applicant]
US 20010029483A1 · Schultz et al. · 2001 [cited by applicant]
US 20010037216A1 · Oscar et al. · 2001 [cited by applicant]
US 20010039589A1 · Aho et al. · 2001 [cited by applicant]
US 20010056359A1 · Abreu · 2001 [cited by applicant]
US 20020002495A1 · Ullman · 2002 [cited by applicant]
US 20020004812A1 · Motoyama · 2002 [cited by applicant]
US 20020032582A1 · Feeney et al. · 2002 [cited by applicant]
US 20020032583A1 · Joao · 2002 [cited by applicant]
US 20020035484A1 · McCormick · 2002 [cited by applicant]
US 20020087583A1 · Morgan et al. · 2002 [cited by applicant]
US 20020111832A1 · Judge · 2002 [cited by applicant]
US 20020133379A1 · Lewis et al. · 2002 [cited by applicant]
US 20020143579A1 · Docherty et al. · 2002 [cited by applicant]
US 20020147614A1 · Doerr et al. · 2002 [cited by applicant]
US 20020188552A1 · Kavounas et al. · 2002 [cited by applicant]
US 20020198831A1 · Patricelli et al. · 2002 [cited by applicant]
US 20030009367A1 · Morrison · 2003 [cited by applicant]
US 20030050796A1 · Baldwin · 2003 [cited by applicant]
US 20030050799A1 · Jay et al. · 2003 [cited by applicant]
US 20030069760A1 · Gelber · 2003 [cited by applicant]
US 20030074234A1 · Stasny · 2003 [cited by applicant]
US 20030097310A1 · Ono et al. · 2003 [cited by applicant]
US 20030130875A1 · Hawash et al. · 2003 [cited by applicant]
US 20030149625A1 · Leonardi et al. · 2003 [cited by applicant]
US 20030154163A1 · Phillips et al. · 2003 [cited by applicant]
US 20030172008A1 · Hage et al. · 2003 [cited by applicant]
US 20030187690A1 · Miller · 2003 [cited by applicant]
US 20030229540A1 · Algiene · 2003 [cited by applicant]
US 20030236747A1 · Sager · 2003 [cited by applicant]
US 20040006490A1 · Gingrich et al. · 2004 [cited by applicant]
US 20040039599A1 · Fralic · 2004 [cited by applicant]
US 20040054685A1 · Rahn et al. · 2004 [cited by applicant]
US 20040059607A1 · Ball et al. · 2004 [cited by applicant]
US 20040073456A1 · Gottlieb et al. · 2004 [cited by applicant]
US 20040073457A1 · Kalies · 2004 [cited by examiner]
US 20040078222A1 · Khan et al. · 2004 [cited by applicant]
US 20040078234A1 · Tallal, Jr. · 2004 [cited by applicant]
US 20040088187A1 · Chudy et al. · 2004 [cited by applicant]
US 20040103062A1 · Wood et al. · 2004 [cited by applicant]
US 20040117323A1 · Mindala · 2004 [cited by applicant]
US 20040148198A1 · Kalies · 2004 [cited by applicant]
US 20040153336A1 · Virdee et al. · 2004 [cited by applicant]
US 20040199545A1 · Wagner et al. · 2004 [cited by applicant]
US 20040236630A1 · Kost et al. · 2004 [cited by applicant]
US 20040249745A1 · Baaren · 2004 [cited by applicant]
US 20050015280A1 · Gabel et al. · 2005 [cited by applicant]
US 20050060201A1 · Connely, III et al. · 2005 [cited by applicant]
US 20050065821A1 · Kalies, Jr. · 2005 [cited by applicant]
US 20050075932A1 · Mankoff · 2005 [cited by applicant]
US 20050080692A1 · Padam et al. · 2005 [cited by applicant]
US 20050102169A1 · Wilson · 2005 [cited by applicant]
US 20050154627A1 · Zuzek et al. · 2005 [cited by applicant]
US 20050187793A1 · Myles · 2005 [cited by applicant]
US 20050197862A1 · Paterson et al. · 2005 [cited by applicant]
US 20050240442A1 · Lapsker et al. · 2005 [cited by applicant]
US 20050240473A1 · Ayers, Jr. et al. · 2005 [cited by applicant]
US 20050261939A1 · Augspurger et al. · 2005 [cited by applicant]
US 20050288972A1 · Marvin et al. · 2005 [cited by applicant]
US 20060020514A1 · Yered · 2006 [cited by applicant]
US 20060026041A1 · Ullman · 2006 [cited by applicant]
US 20060036470A1 · Oaks · 2006 [cited by examiner]
US 20060085231A1 · Brofman · 2006 [cited by applicant]
US 20060085385A1 · Foster et al. · 2006 [cited by applicant]
US 20060113376A1 · Reed et al. · 2006 [cited by applicant]
US 20060149595A1 · Williams et al. · 2006 [cited by applicant]
US 20060149784A1 · Tholl et al. · 2006 [cited by applicant]
US 20060184391A1 · Barre et al. · 2006 [cited by applicant]
US 20060212318A1 · Dooley · 2006 [cited by applicant]
US 20060212345A1 · Soza et al. · 2006 [cited by applicant]
US 20060224414A1 · Astrup et al. · 2006 [cited by applicant]
US 20060224417A1 · Werner · 2006 [cited by applicant]
US 20060224443A1 · Soza et al. · 2006 [cited by applicant]
US 20060235747A1 · Hammond et al. · 2006 [cited by applicant]
US 20060259363A1 · Jhetam et al. · 2006 [cited by applicant]
US 20070005402A1 · Kennedy et al. · 2007 [cited by applicant]
US 20070033137A1 · Provost et al. · 2007 [cited by applicant]
US 20070043589A1 · Warren et al. · 2007 [cited by applicant]
US 20070043595A1 · Pederson · 2007 [cited by applicant]
US 20070050209A1 · Yered · 2007 [cited by applicant]
US 20070050210A1 · Wiley, II · 2007 [cited by examiner]
US 20070067186A1 · Brenner et al. · 2007 [cited by applicant]
US 20070094133A1 · Anandarao et al. · 2007 [cited by applicant]
US 20070108053A1 · Cramer et al. · 2007 [cited by applicant]
US 20070136100A1 · Daugherty et al. · 2007 [cited by applicant]
US 20070162303A1 · Wiley et al. · 2007 [cited by applicant]
US 20070168228A1 · Lawless · 2007 [cited by applicant]
US 20070185799A1 · Harrison et al. · 2007 [cited by applicant]
US 20070191985A1 · Bain · 2007 [cited by applicant]
US 20070194352A1 · Han · 2007 [cited by applicant]
US 20070202886A1 · Dhebri et al. · 2007 [cited by applicant]
US 20070204043A1 · Espinosa et al. · 2007 [cited by applicant]
US 20070219813A1 · Moore · 2007 [cited by applicant]
US 20070233525A1 · Boyle · 2007 [cited by applicant]
US 20070233526A1 · Hoffman et al. · 2007 [cited by applicant]
US 20070239493A1 · Sweetland et al. · 2007 [cited by applicant]
US 20070250341A1 · Howe et al. · 2007 [cited by applicant]
US 20070260750A1 · Feied et al. · 2007 [cited by applicant]
US 20070276697A1 · Wiley et al. · 2007 [cited by applicant]
US 20070294765A1 · Rihn et al. · 2007 [cited by applicant]
US 20070299915A1 · Shraim et al. · 2007 [cited by applicant]
US 20080033750A1 · Swiss et al. · 2008 [cited by applicant]
US 20080103836A1 · Park et al. · 2008 [cited by applicant]
US 20080112411A1 · Stafford et al. · 2008 [cited by applicant]
US 20080152107A1 · Mendiola · 2008 [cited by applicant]
US 20080183492A1 · Warren et al. · 2008 [cited by applicant]
US 20080215361A1 · Nunnari et al. · 2008 [cited by applicant]
US 20080262948A1 · Grady et al. · 2008 [cited by applicant]
US 20090006141A1 · Karr · 2009 [cited by applicant]
US 20090030719A1 · Nadas et al. · 2009 [cited by applicant]
US 20090064330A1 · Shraim et al. · 2009 [cited by applicant]
US 20090083064A1 · Mahinda · 2009 [cited by applicant]
US 20090094051A1 · Ard et al. · 2009 [cited by applicant]
US 20090100099A1 · Buckwalter · 2009 [cited by applicant]
US 20090106313A1 · Boldyga · 2009 [cited by applicant]
US 20090112707A1 · Weiss et al. · 2009 [cited by applicant]
US 20090198510A1 · Ditto · 2009 [cited by applicant]
US 20090204477A1 · Urso · 2009 [cited by applicant]
US 20090287558A1 · Seth et al. · 2009 [cited by applicant]
US 20090313112A1 · Champ et al. · 2009 [cited by applicant]
US 20090327363A1 · Cullen et al. · 2009 [cited by applicant]
US 20100030667A1 · Chudy et al. · 2010 [cited by applicant]
US 20100070298A1 · Kalies · 2010 [cited by applicant]
US 20100144259A1 · Allexon et al. · 2010 [cited by applicant]
US 20100145730A1 · Abreu · 2010 [cited by applicant]
US 20100161353A1 · Mayaud · 2010 [cited by applicant]
US 20100217622A1 · Brown et al. · 2010 [cited by applicant]
US 20100285821A1 · Smeeding et al. · 2010 [cited by applicant]
US 20100287001A1 · Pearce et al. · 2010 [cited by applicant]
US 20100293236A1 · Wisner et al. · 2010 [cited by applicant]
US 20110015978A1 · Welch, Jr. · 2011 [cited by applicant]
US 20110112871A1 · Simonowski et al. · 2011 [cited by applicant]
US 20110161109A1 · Pinsonneault et al. · 2011 [cited by applicant]
US 20110196697A1 · Akers · 2011 [cited by applicant]
US 20110288925A1 · Thomas et al. · 2011 [cited by applicant]
US 20120053958A1 · Marshall et al. · 2012 [cited by applicant]
US 20120136809A1 · Cannata et al. · 2012 [cited by applicant]
US 20120143627A1 · Ruben et al. · 2012 [cited by applicant]
US 20120166268A1 · Griffiths · 2012 [cited by applicant]
US 20120179481A1 · Patel et al. · 2012 [cited by applicant]
US 20120185263A1 · Emert · 2012 [cited by applicant]
US 20120185264A1 · Demogenes et al. · 2012 [cited by applicant]
US 20120253829A1 · John et al. · 2012 [cited by applicant]
US 20120253830A1 · John et al. · 2012 [cited by applicant]
US 20120253831A1 · John et al. · 2012 [cited by applicant]
US 20120253832A1 · John et al. · 2012 [cited by applicant]
US 20120253833A1 · John et al. · 2012 [cited by applicant]
US 20120253846A1 · John · 2012 [cited by examiner]
US 20120265591A1 · Hwang · 2012 [cited by applicant]
US 20120323608A1 · Herzlinger · 2012 [cited by applicant]
US 20130041968A1 · Cohen et al. · 2013 [cited by applicant]
US 20130046610A1 · Abraham · 2013 [cited by applicant]
US 20130103602A1 · Melnick et al. · 2013 [cited by applicant]
US 20130144715A1 · Kranzley et al. · 2013 [cited by applicant]
US 20130179180A1 · Patra · 2013 [cited by applicant]
US 20130197980A1 · Lerner et al. · 2013 [cited by applicant]
US 20130246082A1 · Brylawski et al. · 2013 [cited by applicant]
US 20130311389A1 · Kaehler et al. · 2013 [cited by applicant]
US 20140039911A1 · Iyer · 2014 [cited by applicant]
US 20140088985A1 · Grant et al. · 2014 [cited by applicant]
US 20140214435A1 · Previdi · 2014 [cited by applicant]
US 20140249861A1 · Gamble et al. · 2014 [cited by applicant]
US 20140249864A1 · Sultan et al. · 2014 [cited by applicant]
US 20140278448A1 · Sadeghi et al. · 2014 [cited by applicant]
US 20140278456A1 · Milosevich et al. · 2014 [cited by applicant]
US 20140278531A1 · Gupta · 2014 [cited by applicant]
US 20150032465A1 · Sundar et al. · 2015 [cited by applicant]
US 20150088557A1 · Huynh et al. · 2015 [cited by applicant]
US 20150142479A1 · Porter et al. · 2015 [cited by applicant]
US 20150149197A1 · Guinan · 2015 [cited by applicant]
US 20150154565A1 · Kaehler et al. · 2015 [cited by applicant]
US 20150154588A1 · Purves et al. · 2015 [cited by applicant]
US 20150195224A1 · Karnin et al. · 2015 [cited by applicant]
US 20150213195A1 · Blechman · 2015 [cited by applicant]
US 20150234991A1 · Pinsonneault · 2015 [cited by applicant]
US 20150235177A1 · Shraim et al. · 2015 [cited by applicant]
US 20150269695A1 · Pinsonneault et al. · 2015 [cited by applicant]
US 20150332422A1 · Gilmartin · 2015 [cited by applicant]
US 20150371000A1 · Pinsonneault · 2015 [cited by applicant]
US 20160012465A1 · Sharp · 2016 [cited by applicant]
US 20160103978A1 · Stong · 2016 [cited by applicant]
US 20160140593A1 · Smeeding et al. · 2016 [cited by applicant]
US 20160213512A1 · Palanker et al. · 2016 [cited by applicant]
US 20160267544A1 · Flood et al. · 2016 [cited by applicant]
US 20160267545A1 · Glass et al. · 2016 [cited by applicant]
US 20160307195A1 · Cantwell et al. · 2016 [cited by applicant]
US 20160321406A1 · Timmerman et al. · 2016 [cited by applicant]
US 20160321410A1 · Timmerman et al. · 2016 [cited by applicant]
US 20160358142A1 · Hillen · 2016 [cited by applicant]
US 20160359795A1 · Fehling · 2016 [cited by applicant]
US 20170034087A1 · Borenstein et al. · 2017 [cited by applicant]
US 20170220768A1 · Tanner, Jr. et al. · 2017 [cited by applicant]
US 20170323295A1 · Kranzley et al. · 2017 [cited by applicant]
US 20170324695A1 · Fischer et al. · 2017 [cited by applicant]
US 20170329922A1 · Eberting et al. · 2017 [cited by applicant]
US 20180012244A1 · Leonardi · 2018 [cited by applicant]
US 20180366810A1 · Nero et al. · 2018 [cited by applicant]
US 20190095582A1 · Waits · 2019 [cited by applicant]
US 20190213212A1 · Adato et al. · 2019 [cited by applicant]
US 20190252049A1 · Fotsch et al. · 2019 [cited by applicant]
US 20190385733A1 · Kaye et al. · 2019 [cited by applicant]
US 20190385734A1 · Pinsonneault · 2019 [cited by applicant]
US 20200105392A1 · Karkazis et al. · 2020 [cited by applicant]
US 20200372988A1 · Bezdek et al. · 2020 [cited by applicant]
US 20210319887A1 · Derrick, Jr. et al. · 2021 [cited by applicant]
US 20210374876A1 · Cedergreen · 2021 [cited by applicant]
AU 2003243327A · 2003 [cited by applicant]
CA 2482370A1 · 2006 [cited by applicant]
CA 2792252A1 · 2013 [cited by applicant]
CA 2810686A1 · 2013 [cited by applicant]
CN 102362778 · 2012 [cited by applicant]
KR 100755440 · 2007 [cited by applicant]
KR 100793852 · 2008 [cited by applicant]
KR 101038074 · 2011 [cited by applicant]
KR 101101692 · 2011 [cited by applicant]
KR 20110138108 · 2011 [cited by applicant]
KR 20110138572 · 2011 [cited by applicant]
KR 101154858 · 2012 [cited by applicant]
WO WO1991006917A1 · 1991 [cited by applicant]
WO WO1995003569A2 · 1995 [cited by applicant]
WO WO1997025682A1 · 1997 [cited by applicant]
WO WO1998050871A1 · 1998 [cited by applicant]
WO WO2000039737A1 · 2000 [cited by applicant]
WO WO2003098401A2 · 2003 [cited by applicant]
WO WO2007025295A2 · 2007 [cited by applicant]
WO WO2007094772A1 · 2007 [cited by applicant]
WO WO2008092109A2 · 2008 [cited by applicant]
M. Bowman and S. Acharya, “Risk Assessment of Pharmacies & Electronic Prescriptions,” 2019 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining (ASONAM), Vancouver, BC, Canada, 2019, pp. … [cited by examiner]
C. Gemmil, M. (2008). The price elasticity of demand for prescription drugs: an exploration of demand in different settings (Order No. U615895). Available from ProQuest Dissertations and Theses Professional. (1625984575… [cited by examiner]
S. Liu, J. C. Xu, G. Liu, H. Xue, D. Bishai and Y. Wang, “Evaluating Cost-Effectiveness of Treatment Options for Diabetes Patients Using System Dynamics Modeling,” 2018 Winter Simulation Conference (WSC), Gothenburg, Sw… [cited by examiner]
Tiriveedhi V. Impact of Precision Medicine on Drug Repositioning and Pricing: a too Small to Thrive Crisis. J Pers Med. Nov. 5, 2018;8(4):36. doi: 10.3390/jpm8040036. PMID: 30400625; PMCID: PMC6313451. (Year: 2018). [cited by examiner]
Dubois, Robert W., “Rx Drug Costs: List Prices Versus Net Prices and the Importance of Staying Within the Data”, Health Affairs Blog, Mar. 2019, 7 pages. [cited by applicant]
Kamal, Rabah, et al., “What are the recent and forecasted trends in prescription drug spending?” Peterson-KFF Health System Tracker, Feb. 20, 2019, 19 pages, Peterson Center on Healthcare. [cited by applicant]
Cepeda, Maria Soledad, et al., “Quantification of missing prescriptions in commercial claims databases : results of a cohort study.”, Pharmacoepidemiology and Drug Safety, Apr. 2017, pp. 386-392, vol. 26, Epub Jan. 25, … [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 16/867,286, dated Sep. 8, 2022, 19 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 16/792,413, dated Sep. 8, 2022, 18 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 17/012,565, dated Sep. 21, 2022, 11 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance received for U.S. Appl. No. 16/453,509, dated Oct. 3, 2022, 23 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Final Office Action received for U.S. Appl. No. 17/175,939, dated Oct. 5, 2022, 30 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Nonfinal Office Action received for U.S. Appl. No. 17/162,461, dated Oct. 5, 2022, 47 pages, U.S. [cited by applicant]
United States Patent and Trademark Office, Nonfinal Office Action received for U.S. Appl. No. 17/158,118, dated Oct. 7, 2022, 46 pages, U.S. [cited by applicant]
“Pharmacy Reject Codes” NCPDP, 5 pages. [cited by applicant]
“St. Vincent's first to use Birmingham startup's information system.” the Birmingham News [Online] Apr. 11, 2005. URL: http://www.awarix.com. [cited by applicant]
“St. Vincent's is Digital Flagship” D. Lockridge; Birmingham Medical News [Online] Sep. 2005. [cited by applicant]
“Two automatic identification technology, neither new in the sense if being recent developments . . . ” Patient Safety & Quality Healthcare [Online] Aug. 2005_ URL: http://www_awarix.com. [cited by applicant]
Advisory Action for U.S. Appl. No. 14/193,294 mailed Nov. 9, 2017, 3 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/085,166 dated Apr. 11, 2019, 4 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/085,166 dated Apr. 29, 2020, 3 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/137,371 mailed Feb. 25, 2019, 5 pages. [cited by applicant]
Advisory Action for U.S. Appl. No. 15/427,746 mailed Jul. 2, 2019, 2 pages. [cited by applicant]
Advisory Action received for U.S. Appl. No. 15/085,166, dated Jan. 29, 2021, 3 pages, US. [cited by applicant]
Almaro, Moshe; “Recovery and Reuse of Unused Prescription Drugs” MIT What Matters: Aug. 2005. [cited by applicant]
American Society of Health-System Pharmacists (ASHP), “Is Prescribing the Next Step in the Evolution of Pharmacy?” May 15, 2012. [cited by applicant]
Anonymous, ACS to Demonstrate Electronic Health Record Solution Suite at MMIS 2007 Conference; EHR Tools Consolidate Data, Provide Useful Information at the Point of Care for Medicaid Providers, Payers, and Patients, PR… [cited by applicant]
Anonymous, Medic; On-line Goes In-House, Chain Store Age Executive, Jan. 1987, vol. 63, Issue 1, USA; Abstract only. [cited by applicant]
Anonymous, Pharmacy Industry Leaders Launch Firm to Supply Real-Time Data, PR Newswire, Jul. 30, 2001, p. 1, New York, NY, USA. [cited by applicant]
Anonymous, TechRx Announces Successful Beta Deployment of T-Rex. PR Newswire. May 13, 2002. [cited by applicant]
Chu, Kuan-Yu, et al., “Incremental analysis of the reengineering of an outpatient billing process: an empirical study in a public hospital”, BMC Health Services Research, Jun. 13, 2013, vol. 13, No. 215, 8 pages, BioMed… [cited by applicant]
CMS Updates Drug Dashboards with Prescription Drug Pricing and Spending Data, Data, Medicare Part D, Prescription drugs (Mar. 14, 2019). [cited by applicant]
Consalvo, Bob; “City of Boston in the City Council” hearing notice, Dec. 6, 2006. [cited by applicant]
Coping with Information Overload. The News Source for Healthcare Information Technology [Online] Nov. 2004. URL: http://www.awarix.com. [cited by applicant]
Decision to Grant European Patent Application No. 13809457.8 dated May 18, 2017. [cited by applicant]
Examiner's Answer for U.S. Appl. No. 14/145,027 mailed Sep. 7, 2016, 27 pages. [cited by applicant]
Extended European Search Report for European Application No. 13809457.8 dated Apr. 15, 2016, 6 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/140,015 mailed Jan. 31, 2011, 10 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/415,062 mailed Oct. 6, 2011, 18 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/555,589 mailed Apr. 11, 2012, 17 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/560,071 mailed Aug. 28, 2015, 8 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/560,071 mailed Nov. 8, 2012, 11 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/570,982 mailed Apr. 11, 2014, 22 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/570,982 mailed Aug. 28, 2015, 10 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/570,982 mailed Jan. 17, 2013, 19 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/730,015 mailed Aug. 14, 2012, 10 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 12/978,898 mailed May 16, 2013, 16 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/721,890 mailed Jun. 24, 2015, 14 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/721,890 mailed Nov. 25, 2016, 12 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/782,909 mailed May 31, 2016, 18 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/782,909 mailed Oct. 6, 2015, 24 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/804,175 mailed Oct. 6, 2015, 6 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 13/827,676 mailed Jul. 13, 2015, 17 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/090,113 mailed Jan. 6, 2016, 18 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/090,122 mailed Apr. 22, 2016, 13 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/145,027 mailed Nov. 19, 2015, 12 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/193,294 mailed May 2, 2016, 29 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/218,326 mailed Jun. 30, 2016, 17 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/085,166, dated Dec. 4, 2020, 11 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/137,371 mailed Nov. 28, 2018, 24 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/427,746 mailed Apr. 15, 2019, 9 pages. [cited by applicant]
Google NPL (non-patent literature) Search on “pharmacy payment benefit copay NDC database”, retrieved from the Internet at <https://scholar.google.com/scholar?hl=en&as_sdt=3,47&g=pharmacy+payment+benefit+copay+NDC+datab… [cited by applicant]
Google NPL (non-patent literature) Search on “pharmacy payment benefit copay NDC database”, retrieved from the Internet at <https://www.google.com/search?g=pharmacy+payment+benefit+copay+ndc+database&source=int&tbs=cdr%… [cited by applicant]
Google Patents Search (including Web Search History, Prior Art Search Printable History Generator) on “pharmacy payment benefit copay NDC database) (prescription) (code) (refills) (error code) country:US before:filing:2… [cited by applicant]
Google Scholar Search (including Web Search History, Prior Art Search Printable History Generator) on “pharmacy payment benefit copay NDC database prescription . . . ”, retrieved from the Internet at <https://scholar.go… [cited by applicant]
How to Estimate the Cost of a Prescription. Pam Olson, Sr. Client Services Executive, Navitus Health Solutions (Year: 2015). [cited by applicant]
Kaplan et al., “Let the Needles Do the Talking! Evaluating the New Haven Needle Exchange.” Interfaces 23:1, Jan.-Feb. 1993 (pp. 7-26). [cited by applicant]
Lamb, J., New Era of Electronic Medicine Management: E-Prescriptions, Britain's Traditionally Cautious National Health Service is Starting Trials for Online Prescription, with the Aim of Cutting Costs, Finance Times, Lo… [cited by applicant]
Letter Restarting Period for Response for U.S. Appl. No. 13/721,890 mailed Jan. 14, 2015, 11 pages. [cited by applicant]
Marie Chisholm et al. “Pharmaceutical Manufacturer Assistance Program.” Arch Intern Med. Vol. 162, Apr. 8, 2002. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/560,071 mailed Jun. 21, 2012, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/570,982 mailed Jun. 20, 2012, 10 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/193,294 mailed Feb. 21, 2017, 32 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/085,166 dated Jun. 12, 2020, 26 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/180,915 dated Jun. 1, 2020, 40 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 12/140,015 mailed Oct. 8, 2010, 9 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 12/189,650 mailed Jan. 22, 2010, 11 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 12/189,654 mailed Jan. 22, 2010, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/388,956 mailed Feb. 3, 2011, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/415,062 mailed Mar. 30, 2011, 23 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/555,589 mailed Dec. 9, 2011, 12 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/560,071 mailed Sep. 23, 2014, 17 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/570,982 mailed Sep. 12, 2013, 22 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/730,015 mailed Mar. 6, 2012, 9 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/956,411 mailed Jan. 24, 2011, 9 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/978,898 mailed Feb. 6, 2013, 12 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 12/982,395 mailed Dec. 11, 2012, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/721,890 mailed Jan. 9, 2015, 11 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/721,890 mailed Jun. 14, 2016, 9 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 13/782,909 mailed Feb. 11, 2016, 17 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 13/827,676 mailed Dec. 26, 2014, 13 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 13/827,676 mailed Dec. 30, 2015, 23 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/145,027 mailed Mar. 23, 2015, 13 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/137,371 mailed May 29, 2018, 19 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/427,746 mailed Oct. 18, 2018, 9 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/819,258 dated Sep. 4, 2020, 6 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/085,166, dated Mar. 17, 2021, 11 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/551,962, dated Mar. 2, 2021, 16 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/453,509 mailed Mar. 26, 2021, 45 pages. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/832,318 mailed Apr. 23, 2021, 52 pages. [cited by applicant]